Drugs / Salk IPV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04073459 Comparator | Nov 2019 → Apr 2020 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | LG Chem | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salk IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04073459 ↗ |
| Modality | Vaccine | “Imovax® Polio (Poliomyelitis Vaccine (Inactivated))” NCT04073459 ↗ |
| Route | Intramuscular | “Intramuscular injection into anterolateral area of the thigh” NCT04073459 ↗ |